A notable advancement in blood sugar treatment is emerging with the approval of tirzepatide at a dosage of 45mg. This new version builds upon the existing success of tirzepatide, a dual GIP and GLP-1 target, and https://socialstrategie.com/story7114668/groundbreaking-introduction-tirzepatide-45mg-for-glucose-regulation